The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2020 ASCO Highlights on NSCLC Targeted Therapy: T-DXd for HER2-Mutated, Capmatinib for MET-Amplified, Selpercatinib (LOXO-292) for RET-Altered, Adjuvant Osimertinib for EGFR+ Disease

0 views
September 9, 2020
Comments 0
Login to view comments. Click here to Login